Amneal Pharmaceuticals (NYSE:AMRX) Earns Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Amneal Pharmaceuticals (NYSE:AMRX – Free Report) in a research note published on Wednesday. The firm issued a buy rating on the stock. Other research analysts have also issued reports about the stock. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $4.00 to $5.00 and gave the […]

Related Keywords

New York ,United States ,Andrews Boyer ,Piper Sandler ,Smith Anglin Financial ,Amneal Pharmaceuticals Inc ,York Life Investment Management ,Analyst Recommendations For Amneal Pharmaceuticals ,Allspring Global Investments Holdings ,News Ratings For Amneal Pharmaceuticals Daily ,Amneal Pharmaceuticals ,Hedges Asset Management ,Securities Exchange Commission ,Barclays ,Amneal Pharmaceuticals Stock Down ,Institutional Trading Of Amneal Pharmaceuticals ,Free Report ,Moderate Buy ,Pharmaceuticals Stock Down ,Get Free Report ,Exchange Commission ,Asset Management ,Global Investments Holdings ,Amneal Pharmaceuticals Daily ,Nyse Amrx ,Amrx ,Medical ,Initiated Coverage ,Stocknews Com ,